Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, specifically dated February 17, 2022. The report serves as a notification regarding the vesting of awards under the GSK Deferred Investment Award programme for Persons Discharging Managerial Responsibilities (PDMRs). The awards, originally granted on September 3, 2019, vested on February 14, 2022, contingent upon continued employment.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. The only financial data disclosed relates to specific executive compensation transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Cash payment in lieu of notional ordinary shares following vesting.
- Price per Share: £15.712.
- Volume: 10,050 notional shares per executive.
- Total Cash Payment: £157,905.60 per executive (subject to tax withholding).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents the execution of a pre-existing deferred investment award plan for two specific executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. The document is a regulatory disclosure of a specific transaction event.
Important Facts for Investors
- Executives Involved: Ms. D. Conrad (Chief People Officer) and Ms. S. Jackson (SVP, Global Communication and CEO Office).
- Transaction Date: February 14, 2022.
- Settlement Method: Both executives received cash payments rather than physical shares, totaling £157,905.60 each before tax.
- Programme Details: The awards were part of the 2019 Deferred Investment Award programme and required continued employment to vest.
- Financial Scope: This filing does not contain company-wide financial performance data.